Abstract
Animal models of BCR–ABL+ leukemias have provided important new knowledge about the molecular pathophysiology of these diseases, and answered questions that are difficult or impossible to address using BCR–ABL-expressing cell lines or primary Ph+ leukemia samples from patients. The power of mouse models lies in their ability to recapitulate precisely the phenotypes of BCR–ABL+ leukemias in vivo, but this comes at the price of significant complexity. Here I review recent studies of leukemias induced in mice by BCR–ABL with an emphasis on the intricate nature of these diseases and the need for careful pathological and molecular analysis.
Similar content being viewed by others
References
Anderson SM, Mladenovic J . 1996 Blood 87: 238–244
Andreasson P, Johansson B, Carlsson M, Jarlsfelt I, Fioretos T, Mitelman F, Hoglund M . 1997 Genes Chrom. Cancer 20: 299–304
Brunel V, Sainty D, Carbuccia N, Mozzicolacci M, Fernandez F, Simonetti J, Gabert J, Dubreuil P, Lafage-Pochitaloff M, Birg F . 1996 Leukemia 10: 2003
Carlesso N, Frank DA, Griffin JD . 1996 J. Exp. Med. 183: 811–820
Chung S-W, Wong PMC, Durkin H, Wu Y-S, Petersen J . 1991 Proc. Natl. Acad. Sci. USA 88: 1585–1589
Cortez D, Reuther G, Pendergast AM . 1997 Oncogene 15: 2333–2342
Daley G, Baltimore D . 1988 Proc. Natl. Acad. Sci. USA 85: 9312–9316
Daley GQ, Van Etten RA, Baltimore D . 1990 Science 247: 824–830
Daley GQ, Van Etten RA, Baltimore D . 1991 Proc. Natl. Acad. Sci. USA 88: 11335–11338
Dickens M, Rogers J, Cavanagh J, Raitano A, Xia Z, Halpern JR, Greenberg ME, Sawyers CL, Davis RJ . 1997 Science 277: 693–696
Elefanty AG, Cory S . 1992 Mol. Cell. Biol. 12: 1755–1763
Elefanty AG, Hariharan IK, Cory S . 1990 EMBO J. 9: 1069–1078
Era T, Witte ON . 2000 Proc. Natl. Acad. Sci. USA 97: 1737–1742
Franz WM, Berger P, Wang JYJ . 1989 EMBO J. 8: 137–147
Golub TR, Barker GF, Lovett M, Gilliland DG . 1994 Cell 77: 307–316
Golub TR, Goga A, Barker GF, Afar DEH, McLaughlin J, Bohlander SK, Rowley JD, Witte ON, Gilliland DG . 1996 Mol. Cell. Biol. 16: 4107–4116
Groopman JE, Golde DW . 1981 Ann. Int. Med. 94: 95–107
Gross AW, Ren R . 2000 Oncogene 19: 6286–6296
Han X, Wong PMC, Chung S-W . 1991 Proc. Natl. Acad. Sci. USA 88: 10129–10133
Hannemann JR, McManus DM, Kabarowski JHS, Wiedemann LW . 1998 Br. J. Haematol. 102: 475–485
Hariharan IK, Adams JM, Cory S . 1988 Oncogene Res. 3: 387–399
Ilaria RL, Van Etten RA . 1995 Blood 86: 3897–3904
Ilaria RL, Van Etten RA . 1996 J. Biol. Chem. 271: 31704–31710
Jackson P, Baltimore D . 1989 EMBO J. 8: 449–456
Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C . 1999 Proc. Natl. Acad. Sci. USA 96: 12804–12809
Jousset C, Carron C, Boureux A, Quang CT, Oury C, Dusanter-Fourt I, Charon M, Levin J, Bernard O, Ghysdael J . 1997 EMBO J. 16: 69–82
Kelliher MA, McLaughlin J, Witte ON, Rosenberg N . 1990 Proc. Natl. Acad. Sci. USA 87: 6649–6653
Kelly LM, Liu Q, Kutok JL, Williams IR, Boulton CL, Gilliland DG . 2002 Blood 99: 310–318
Kipreos ET, Wang JYJ . 1992 Science 256: 382–385
Laneuville P, Heisterkamp N, Groffen J . 1991 Oncogene 6: 275–282
Li S, Gillessen S, Tomasson MH, Dranoff G, Gilliland DG, Van Etten RA . 2001 Blood 97: 1442–1450
Li S, Ilaria RL, Million RP, Daley GQ, Van Etten RA . 1999 J. Exp. Med. 189: 1399–1412
Liu J, Wu Y, Ma GZ, Lu D, Haataja L, Heisterkamp N, Groffen J, Arlinghaus RB . 1996 Mol. Cell. Biol. 16: 998–1005
Lugo TG, Pendergast A, Muller AJ, Witte ON . 1990 Science 247: 1079–1082
Lugo TG, Witte ON . 1989 Mol. Cell. Biol. 9: 1263–1270
Maru Y, Witte ON . 1991 Cell 67: 459–468
Mayer BJ, Jackson PK, Van Etten RA, Baltimore D . 1992 Mol. Cell. Biol. 12: 609–618
McLaughlin J, Chianese E, Witte ON . 1987 Proc. Natl. Acad. Sci. USA 84: 6558–6562
McWhirter JR, Galasso DL, Wang JYJ . 1993 Mol. Cell. Biol. 13: 7587–7595
McWhirter JR, Wang JYJ . 1993 EMBO J. 12: 1533–1546
Million RP, Aster J, Gilliland DG, Van Etten RA . 2002 Blood 99: 4568–4577
Million RP, Van Etten RA . 2000 Blood 96: 664–670
Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B, Skorski T . 1999 J. Exp. Med. 189: 1229–1242
Okuda K, Golub TG, Gilliland DG, Griffin JD . 1996 Oncogene 13: 1147–1152
Papadopoulos P, Ridge SA, Boucher CA, Stocking C, Wiedemann LM . 1995 Cancer Res. 55: 34–38
Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC, Pendergast AM, Bronson R, Aster JC, Scott ML, Baltimore D . 1998 Blood 92: 3780–3792
Pendergast AM, Gishizky ML, Havlik MH, Witte ON . 1993a Mol. Cell. Biol. 13: 1728–1736
Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON . 1991 Cell 66: 161–171
Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CJ, Schlessinger J, Gishizky ML . 1993b Cell 75: 175–185
Perlingeiro RC, Kyba M, Daley GQ . 2001 Development 128: 4597–4604
Peters DG, Klucher KM, Perlingeiro RC, Dessain SK, Koh EY, Daley GQ . 2001 Oncogene 20: 2636–2646
Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG, Arlinghaus R, Pawson T . 1994 EMBO J. 13: 764–773
Raitano AB, Halpern JR, Hambuch TM, Sawyers CL . 1995 Proc. Natl. Acad. Sci. USA 92: 11746–11750
Ren R, Zheng SY, Baltimore D . 1994 Genes Dev. 8: 783–795
Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin ASJ . 1998 Genes Dev. 12: 968–981
Roumiantsev S, de Aos I, Varticovski L, Ilaria RL, Van Etten RA . 2001 Blood 97: 4–13
Sawyers CL, Callahan W, Witte ON . 1992 Cell 70: 901–910
Sawyers CL, McLaughlin J, Witte ON . 1995 J. Exp. Med. 181: 307–313
Schwaller J, Frantsve J, Aster J, Williams IR, Tomasson MH, Ross TS, Van Rompey L, Peeters P, Van Etten RA, Ilaria Jr R, Marynen P, Gilliland DG . 1998 EMBO J. 17: 5321–5333
Scott ML, Van Etten RA, Daley GQ, Baltimore D . 1991 Proc. Natl. Acad. Sci. USA 88: 6506–6510
Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL . 1996 Oncogene 13: 247–254
Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen S-C, Zon G, Gewirtz AM, Perussia B, Calabretta B . 1995a Blood 86: 726–736
Skorski T, Nieborowska-Skorska M, Szczylik C, Kasnakaraj P, Perrotti D, Zon G, Gewirtz A, Perussia B, Calabretta B . 1995b Cancer Res. 55: 2275–2278
Tomasson MH, Sternberg DW, Williams IR, Carroll M, Cain D, Aster JC, Ilaria RL, Van Etten RA, Gilliland DG . 2000 J. Clin. Invest. 105: 423–432
Tomasson MH, Williams IR, Li S, Kutok J, Gillessen S, Dranoff G, Van Etten RA, Gilliland DG . 2001 Blood 97: 1435–1441
Van Etten RA . 2001 Curr. Oncol. Rep. 3: 228–237
Van Etten RA, Debnath J, Zhou H, Casasnovas JM . 1995 Oncogene 10: 1977–1988
Van Etten RA, Jackson PK, Baltimore D, Sanders MC, Matsudaira PT, Janmey PA . 1994 J. Cell Biol. 124: 325–340
van Limbergen H, Beverloo HB, van Drunen E, Janssens A, Hahlen K, Poppe B, van Roy N, Marynen P, de Paepe A, Slater R, Speleman F . 2001 Genes Chrom. Cancer 30: 274–282
Varticovski L, Daley G, Jackson P, Baltimore D, Cantley L . 1991 Mol. Cell. Biol. 11: 1107–1113
Voss J, Posern G, Hannemann JR, Wiedemann LM, Turhan AG, Poirel H, Bernard O, Adermann K, Kardinal C, Feller SM . 2000 Oncogene 19: 1684–1690
Wen S-T, Jackson PK, Van Etten RA . 1996 EMBO J. 15: 1583–1595
Wu Y, Liu J, Arlinghaus RB . 1998 Oncogene 16: 141–146
Zhang X, Ren R . 1998 Blood 92: 3829–3840
Acknowledgements
I thank the members of my laboratory, past and present, for their essential contributions to many of the papers discussed herein, and apologize to colleagues whose work was not cited due to space limitations. Special thanks to Drs George Daley, Warren Pear, and Gary Gilliland for many helpful discussions. This work was supported by NIH grant CA90576 and grants from the Leukemia and Lymphoma Society. RA Van Etten is a Scholar of the Leukemia and Lymphoma Society and the Carl and Margaret Walter Scholar in Blood Research at Harvard Medical School.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Van Etten, R. Studying the pathogenesis of BCR–ABL+ leukemia in mice. Oncogene 21, 8643–8651 (2002). https://doi.org/10.1038/sj.onc.1206091
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206091
- Springer Nature Limited
Keywords
This article is cited by
-
Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets
Leukemia (2021)
-
Differential signaling networks of Bcr–Abl p210 and p190 kinases in leukemia cells defined by functional proteomics
Leukemia (2017)
-
The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase
BMC Cancer (2016)
-
Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-γ1-driven activation of mTOR/p70S6-kinase pathway
Oncogene (2010)
-
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia
Nature Genetics (2004)